346 related articles for article (PubMed ID: 10738907)
1. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
Jankun J; Skrzypczak-Jankun E
Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
[TBL] [Abstract][Full Text] [Related]
2. Lysine 156 promotes the anomalous proenzyme activity of tPA: X-ray crystal structure of single-chain human tPA.
Renatus M; Engh RA; Stubbs MT; Huber R; Fischer S; Kohnert U; Bode W
EMBO J; 1997 Aug; 16(16):4797-805. PubMed ID: 9305622
[TBL] [Abstract][Full Text] [Related]
3. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
4. Binding site of amiloride to urokinase plasminogen activator depends on species.
Jankun J; Skrzypczak-Jankun E
Int J Mol Med; 2001 Oct; 8(4):365-71. PubMed ID: 11562773
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice.
Jankun J; Keck RW; Skrzypczak-Jankun E; Swiercz R
Cancer Res; 1997 Feb; 57(4):559-63. PubMed ID: 9044824
[TBL] [Abstract][Full Text] [Related]
6. The cowpox virus serpin SPI-3 complexes with and inhibits urokinase-type and tissue-type plasminogen activators and plasmin.
Turner PC; Baquero MT; Yuan S; Thoennes SR; Moyer RW
Virology; 2000 Jul; 272(2):267-80. PubMed ID: 10873770
[TBL] [Abstract][Full Text] [Related]
7. Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
Wang Q; Shaltiel S
BMC Biochem; 2003 Jul; 4():5. PubMed ID: 12848892
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor.
Towle MJ; Lee A; Maduakor EC; Schwartz CE; Bridges AJ; Littlefield BA
Cancer Res; 1993 Jun; 53(11):2553-9. PubMed ID: 8495419
[TBL] [Abstract][Full Text] [Related]
9. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ
J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954
[TBL] [Abstract][Full Text] [Related]
10. A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue.
Andersen LM; Wind T; Hansen HD; Andreasen PA
Biochem J; 2008 Jun; 412(3):447-57. PubMed ID: 18318660
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA).
Matthews H; Ranson M; Tyndall JD; Kelso MJ
Bioorg Med Chem Lett; 2011 Nov; 21(22):6760-6. PubMed ID: 21978672
[TBL] [Abstract][Full Text] [Related]
12. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1.
Zhao G; Yuan C; Wind T; Huang Z; Andreasen PA; Huang M
J Struct Biol; 2007 Oct; 160(1):1-10. PubMed ID: 17692534
[TBL] [Abstract][Full Text] [Related]
14. Evidence for the regulation of urokinase and tissue type plasminogen activators by the serpin, protein C inhibitor, in semen and blood plasma.
España F; Estellés A; Fernández PJ; Gilabert J; Sánchez-Cuenca J; Griffin JH
Thromb Haemost; 1993 Dec; 70(6):989-94. PubMed ID: 8165623
[TBL] [Abstract][Full Text] [Related]
15. The crystal structures of 3-TAPAP in complexes with the urokinase-type plasminogen activator and picrate.
Zesławska E; Jacob U; Stürzebecher J; Oleksyn BJ
Bioorg Med Chem Lett; 2006 Jan; 16(1):228-34. PubMed ID: 16202591
[TBL] [Abstract][Full Text] [Related]
16. Ab initio molecular orbital calculations on specific interactions between urokinase-type plasminogen activator and its receptor.
Nagase K; Kobayashi H; Yoshikawa E; Kurita N
J Mol Graph Model; 2009 Aug; 28(1):46-53. PubMed ID: 19403319
[TBL] [Abstract][Full Text] [Related]
17. Role of astrocyte-derived tissue-type plasminogen activator in the regulation of endotoxin-stimulated nitric oxide production by microglial cells.
Vincent VA; Löwik CW; Verheijen JH; de Bart AC; Tilders FJ; Van Dam AM
Glia; 1998 Feb; 22(2):130-7. PubMed ID: 9537833
[TBL] [Abstract][Full Text] [Related]
18. Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).
Katz BA; Luong C; Ho JD; Somoza JR; Gjerstad E; Tang J; Williams SR; Verner E; Mackman RL; Young WB; Sprengeler PA; Chan H; Mortara K; Janc JW; McGrath ME
J Mol Biol; 2004 Nov; 344(2):527-47. PubMed ID: 15522303
[TBL] [Abstract][Full Text] [Related]
19. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.
Katz BA; Sprengeler PA; Luong C; Verner E; Elrod K; Kirtley M; Janc J; Spencer JR; Breitenbucher JG; Hui H; McGee D; Allen D; Martelli A; Mackman RL
Chem Biol; 2001 Nov; 8(11):1107-21. PubMed ID: 11731301
[TBL] [Abstract][Full Text] [Related]
20. Catalytic domain structure of vampire bat plasminogen activator: a molecular paradigm for proteolysis without activation cleavage.
Renatus M; Stubbs MT; Huber R; Bringmann P; Donner P; Schleuning WD; Bode W
Biochemistry; 1997 Nov; 36(44):13483-93. PubMed ID: 9354616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
